NYRADA INC (ASX:NYR) 4 Nyrada Overview Drug development programs Nyrada is developing novel, high value small molecule drugs: Upcoming catalysts Cholesterol Lowering Program Brain Injury Program Identification of alternative PCSK9 inhibitor candidates. Preclinical assessment of alternative target PCSK9 inhibitor candidate. Phase 1 in-human study. Walter Reed (US) Army Institute of Research Traumatic Brain Injury efficacy study. Drug Candidate Indication Aim Target Market NYX-1492 (PCSK9i) Oral PCSK9 inhibitor CholesterolLowering Best-in-class small molecule drug to disrupt and broaden the class in cardiovascular management, offering the convenience of a pill >18M patients (US)1 NYR-BI03 TRPC 3/6/7 blocker Brain Injury First-in-class treatment to prevent secondary brain injury and reduce disability following moderate-severe TBI, concussion, or stroke ~5.5M patients/ year (globally)2
RkJQdWJsaXNoZXIy MjE2NDg3